“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Saturday, August 30, 2025

Barr Laboratories


Barr Laboratories products


A

  • Azithromycin – Antibiotic (macrolide class)

  • Acetaminophen + Hydrocodone – Pain relief (opioid combination)

B

  • Benazepril + Hydrochlorothiazide – Hypertension (ACE inhibitor + diuretic)

C

  • Citalopram – Antidepressant (SSRI)

  • Chlordiazepoxide HCl – Anxiety, alcohol withdrawal (benzodiazepine)

D

  • Didanosine (Videx EC) – HIV treatment (delayed-release antiretroviral)

  • Dextroamphetamine combinations – ADHD, narcolepsy (CNS stimulants)

E

  • Erythropoietin (biosimilar) – Anemia treatment (across select markets)

F

  • Fluvoxamine – Obsessive-compulsive disorder, depression (SSRI)

  • Fenofibrate – High cholesterol, hypertriglyceridemia (fibrate class)

G

  • Gabapentin – Seizures, neuropathic pain (GABA analog)

H

  • Hydroxyzine pamoate – Anxiety, pruritus (antihistamine)

I

  • Isoniazid – Tuberculosis infection (first-line anti-TB therapy)

L

  • Leucovorin Calcium – Antidote in methotrexate toxicity; adjunct in chemotherapy

M

  • Metformin XR 750 mg – Type 2 diabetes (extended-release formulation)

N

  • Norethindrone/Ethinyl Estradiol combos – Oral contraceptives (multiple generic versions)

S

  • SEASONALE (levonorgestrel + ethinyl estradiol) – Extended-cycle oral contraceptive (proprietary)

  • Plan B (levonorgestrel) – Emergency contraceptive (proprietary)

  • Cenestin – Synthetic conjugated estrogens (proprietary)

T

  • Tamoxifen citrate – Breast cancer treatment (generic)

  • Tri-Sprintec – Generic combined oral contraceptive

V

  • Videx EC (Didanosine delayed-release) – Highlighted under D above




No comments:

Post a Comment